Patients with Multiple Endocrine Neoplasia Type 1 most commonly die from metastatic pancreatic neuroendocrine tumors. Prognostic factors for pancreatic neuroendocrine tumors are mainly unclear, except from tumor size. The purpose of the current study was to examine potential differences in prognosis between patients with resected multiple endocrine neoplasia type 1 related nonfunctioning pancreatic neuroendocrine tumors and those with resected multiple endocrine neoplasia type 1 related insulinomas. Databases were searched for patients who had multiple endocrine neoplasia type 1–related pancreatic neuroendocrine tumors removed. Regression was used to evaluate the liver metastases-free survival between patients with insulinomas and non-functioning pancreatic neuroendocrine tumors, as well as to determine the risk variables for this survival.
